Drugs / Inlexisertib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04892017 | Jun 2021 → Mar 2026 | metastatic neoplasm, non-small cell lung carcinoma | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05957367 | Sep 2023 → Mar 2027 expected | gastrointestinal stromal tumor | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inlexisertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05957367 ↗ |
| Known as | DCC-3116 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068018 ↗ |
| Modality | Small molecule | — CHEMBL6068018 ↗ |
| Route | Oral | “Oral Tablet Formulation” NCT04892017 ↗ |